Concepedia

Pharmacogenetics and obesity: common gene variants influence weight loss response of the norepinephrine/dopamine transporter inhibitor GW320659 in obese subjects

Colin F. Spraggs, Sreekumar Pillai, David J. Dow, Christal Douglas, Linda McCarthy, Penelope K. Manasco, Michael J. Stubbins, Allen D. Roses

Pharmacogenetics and Genomics · 2005 · 18 citations · 21 references

DOI

Abstract

Polymorphisms in SLC6A2 and GRIN1 could be used to maximize effective obesity pharmacotherapy by norepinephrine/dopamine transporter inhibitors by identifying patients that may be predisposed to particularly good treatment weight loss response.

References

21

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

W. P. T. James, Arne Astrup, Nick Finer et al. · The Lancet · 2000 · 817 citations

, , +8

Clinical application of pharmacogenetics

Brian B. Spear, Margo Heath‐Chiozzi, Jeffrey Huff · Trends in Molecular Medicine · 2001 · 638 citations

, , +5

The Role of a Common Variant of the Cholesteryl Ester Transfer Protein Gene in the Progression of Coronary Atherosclerosis

Jan Albert Kuivenhoven, J. Wouter Jukema, Aeilko H. Zwinderman et al. · New England Journal of Medicine · 1998 · 627 citations · Full text

Orthostatic Intolerance and Tachycardia Associated with Norepinephrine-Transporter Deficiency

J. R. Shannon, Nancy Flattem, Jens Jordan et al. · New England Journal of Medicine · 2000 · 591 citations · Full text

Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment

Jeffrey M. Drazen, Chandri Yandava, Louise M. Dubé et al. · Nature Genetics · 1999 · 566 citations

, , +9